Pfizer Closes $43B Acquisition Deal with Cancer Drug Maker Seagen
Pfizer has been on an acquisition spree as it seeks to cushion the impact of a projected $17 billion revenue drop by 2030. Pfizer Inc (NYSE: PFE) has closed a $43 billion deal to acquire biotechnology company Seagen Inc and its leading line of cancer drugs. The deal comes as revenue
Read More